Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Multivariate analysis of predictors for OS and LCSS

From: Propensity score-matching analysis of postoperative radiotherapy for stage IIIA-N2 non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database

Variable Before PSM After PSM
OS LCSS OS LCSS
Hazard ratio (95% CI) p Hazard ratio (95% CI) p Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Age (versus <60 years)
 60–79 years 0.822 (0.742–0.911) 0.000 0.809 (0.723–0.904) 0.000 0.758 (0.648–0.887) 0.001 0.716 (0.604–0.850) 0.000
 ≥80 years 1.007 (0.844–1.201) 0.938 1.059 (0.878–1.277) 0.548 0.962 (0.730–1.267) 0.781 0.977 (0.727–1.313) 0.876
Gender (versus Male) 1.066 (0.974–1.168) 0.163 1.049 (0.951–1.158) 0.337 1.030 (0.895–1.186) 0.676 1.030 (0.884–1.202) 0.703
Race (versus White) 1.033 (0.923–1.157) 0.570 1.043 (0.922–1.179) 0.504 1.085 (0.912–1.291) 0.357 1.108 (0.917–1.339) 0.289
Marital status (versus Married) 1.001 (0.912–1.099) 0.984 0.966 (0.872–1.070) 0.511 1.160 (1.000–1.344) 0.049 1.173 (0.999–1.378) 0.052
Insurance (versus insured) 0.970 (0.883–1.065) 0.519 0.995 (0.899–1.101) 0.924 0.844 (0.730–0.977) 0.023 0.877 (0.748–1.027) 0.104
Laterality (versus left) 1.021 (0.929–1.121) 0.671 1.061 (0.958–1.175) 0.257 1.048 (0.906–1.212) 0.530 1.107 (0.943–1.298) 0.213
Location (versus upper lobe)
 Lower lobe 1.025 (0.812–1.294) 0.834 1.027 (0.800–1.317) 0.835 1.137 (0.807–1.601) 0.463 1.076 (0.737–1.570) 0.706
 Middle lobe 1.059 (0.960–1.167) 0.251 1.024 (0.921–1.139) 0.660 0.996 (0.857–1.158) 0.961 0.958 (0.813–1.130) 0.612
Tumor size 1.005 (1.003–1.008) 0.000 1.006 (1.003–1.008) 0.000 1.007 (1.003–1.012) 0.000 1.009 (1.005–1.014) 0.000
Regional LN positive 1.034 (1.014–1.054) 0.001 1.040 (1.019–1.062) 0.000 1.053 (1.020–1.087) 0.002 1.069 (1.033–1.107) 0.000
Regional LN examined 0.995 (0.987–1.004) 0.261 0.993 (0.984–1.002) 0.136 0.994 (0.981–1.007) 0.370 0.988 (0.973–1.003) 0.121
% of LN positive 1.902 (1.490–2.429) 0.000 1.965 (1.507–2.562) 0.000 1.562 (1.041–2.342) 0.031 1.560 (0.997–2.439) 0.051
Histology (versus Adenocarcinoma)
 Squamous cell carcinoma 1.183 (1.058–1.323) 0.003 1.133 (1.002–1.282) 0.046 1.278 (1.077–1.516) 0.005 1.213 (1.004–1.467) 0.045
 Adenosquamous and Large cell carcinoma 1.278 (1.069–1.527) 0.007 1.300 (1.073–1.575) 0.007 1.256 (0.964–1.637) 0.092 1.335 (1.007–1.771) 0.045
Differentiation grade (versus Well differentiated)
 Moderately differentiated 1.118 (0.901–1.387) 0.310 1.149 (0.906–1.458) 0.251 1.051 (0.703–1.570) 0.809 1.117 (0.717–1.741) 0.625
 Poorly differentiated 1.245 (1.002–1.546) 0.048 1.284 (1.011–1.631) 0.041 1.168 (0.781–1.745) 0.449 1.238 (0.794–1.929) 0.346
 Undifferentiated 1.371 (0.969–1.942) 0.075 1.377 (0.940–2.018) 0.101 1.434 (0.799–2.571) 0.227 1.526 (0.809–2.880) 0.192
Surgical procedure (versus Sublobectomy)
 Lobectomy 0.786 (0.664–0.930) 0.005 0.769 (0.641–0.922) 0.005 0.659 (0.500–0.868) 0.003 0.613 (0.456–0.825) 0.001
 Pneumonectomy 0.778 (0.619–0.978) 0.032 0.757 (0.590–0.970) 0.028 0.515 (0.344–0.771) 0.001 0.487 (0.315–0.753) 0.001
T stage (sixth edition) (versus T1)
 T2 1.224 (1.090–1.375) 0.001 1.224 (1.078–1.390) 0.002 1.165 (0.971–1.397) 0.100 1.160 (0.950–1.417) 0.145
 T3 1.816 (1.477–2.233) 0.000 1.960 (1.574–2.440) 0.000 1.747 (1.249–2.443) 0.001 1.812 (1.263–2.598) 0.001
PORT (versus No PORT) 0.846 (0.769–0.932) 0.001 0.838 (0.755–0.931) 0.001 0.793 (0.690–0.912) 0.001 0.837 (0.719–0.975) 0.022
  1. LN lymph node, PSM propensity score-matching, OS overall survival, LCSS lung cancer specific survival, PORT postoperative radiotherapy, CI confidence interval